The FDA has appointed permanent leaders for its Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER), naming Dr. Peter Mikhail and Dr. Janet Davis to these pivotal roles. This decision follows nearly two years of significant turnover within the agency’s leadership, which has raised concerns about stability and direction in regulatory oversight.
These appointments are seen as a strategic move to restore confidence among industry stakeholders, particularly in the wake of heightened scrutiny and evolving regulatory challenges. Analysts suggest that the continuity in leadership could facilitate more consistent policy implementation and foster stronger relationships with pharmaceutical companies navigating the complex landscape of drug development and approval.
As CBER and CDER play critical roles in ensuring the safety and efficacy of biologics and pharmaceuticals, the stability brought by Mikhail and Davis is expected to enhance operational efficiency and support ongoing initiatives aimed at expediting the review process for innovative therapies.
Use the database as your supply chain compass →
